Cullinan Therapeutics, Inc. CGEM Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$49.66M-2.4% | -$50.71M-6.4% | -$50.61M-24.8% | -$70.06M-66.7% | -$48.5M-29.9% | ||
| $79K+3.9% | $79K+2.6% | $79K+3.9% | $77K0.0% | $76K0.0% | ||
| $7.62M-18.8% | $7.31M-24.1% | $9.47M+0.4% | $9.89M-6.1% | $9.37M+13.9% | ||
| $1.67M-3.1% | -$879K-103% | —— | —— | $1.72M+41.7% | ||
| $662K+138% | -$840K-151% | -$798K— | -$3.52M-236% | -$1.74M-324% | ||
| -$46.05M-6.7% | -$38.11M-4.0% | -$36.88M-8.0% | -$57.61M-58.7% | -$43.16M-12.8% | ||
| —— | $11K— | —— | —— | —— | ||
| $20.14M-84.0% | $19.6M-88.3% | $12.57M-87.0% | $78.53M-75.8% | $125.84M-4.2% | ||
| $32.41M-11.9% | $22.39M— | $67.39M— | $53.4M+129% | $36.81M+184% | ||
| —— | $0-100% | $0-100% | —— | —— | ||
| —— | $0— | $0-100% | —— | —— | ||
| $380K— | $715K-54.8% | $0-100% | $373K-99.9% | $0-100% | ||
| -$13.25M-109% | —— | $30.52M+336% | -$3.84M-109% | -$6.35M+73.8% | ||
| —— | —— | —— | -$2.97M— | $0+100% | ||
| -$4.31M+18.0% | $6.18M-10.3% | $5.49M+8,948% | $1.61M-55.2% | -$5.26M+30.2% | ||
| $662K+138% | -$840K-151% | -$798K— | -$3.52M-236% | -$1.74M-324% | ||
| $380K— | $715K-54.8% | $0-100% | $373K-88.8% | $0-100% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cullinan Therapeutics, Inc. generate?
- Cullinan Therapeutics, Inc. (CGEM) generated -$178.6M in operating cash flow over the trailing twelve months.
- What is Cullinan Therapeutics, Inc.'s free cash flow?
- After $11.0K of capital expenditures, Cullinan Therapeutics, Inc.'s free cash flow was -$145.2M over the trailing twelve months, down 19.4% year over year.
- Where does Cullinan Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.